

A New Insight into Nosocomial Infections: a Worldwide Crisis

Elham Sheykhsharan^{1, 2, 3} , Hamed Ebrahimzadeh Leylabadlo⁶ , Farbod Alinezhad^{4, 5} , Hadi Feizi^{3, 4} ,
Hossein Bannazadeh Baghi^{1, 2, 4*} 

¹Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; ²Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; ³Students' Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; ⁴Department of Bacteriology, Faculty of Medicine, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; ⁵Drug Applied Research Center, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; ⁶Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

ARTICLE INFO

Review Article

Keywords: Nosocomial infections, Antibiotic resistance, Bacterial and viral infections, Prevention and control

Received: 30 Nov. 2021

Received in revised form: 07 Apr. 2022

Accepted: 16 Apr. 2022

DOI: 10.52547/JoMMID.10.2.64

*Correspondence

Email: manuscriptacademic@gmail.com

Tel: +984133364661

Fax: +984133364661

© The Author(s)



ABSTRACT

The term "Nosocomial" is attributed to the diseases acquired by the patient under medical care. Various microorganisms, including bacteria, viruses, and fungi, may contribute to developing nosocomial infections (NIs). Urinary tract infections (UTI), surgical-site infections (SSI), bloodstream infections (BSI), and pneumonia are the most well-known instances. We investigated various aspects of NIs and the main causative agents of NIs, particularly bacteria, antibiotic resistance, crucial viral infections in hospitals, and a brief survey of fungal infections. It was concluded that specific human body tissues such as those in the lungs and urinary tract are more likely to be a target for nosocomial pathogens. The fatalities associated with these infections, particularly in the intensive care unit (ICU), are serious concerns, and transmission by health facilities has become a primary medical issue because of its spread into the community. Another medical point is antibiotic resistance which is a leading cause of prolonged periods of hospitalization and makes the treatment procedure harder and costlier. Additionally, measures to prevent the spread of NIs and minimize the economic loss are discussed. All physicians and medical students must be updated about different kinds of these infections, their causative agents, challenges, and how to deal with them to reduce the consequences and improve public health.

INTRODUCTION

Nosocomial infections (NIs) affect hospitalized patients in all clinical centers and hospital wards [1]. NIs, as a global medical problem, account for about 7% and 10% of all infections in developed and developing countries [2]. Bacteria, viruses, and fungi are the underlying causes of hospital-acquired infections; however, bacteria are the main causative agents in 90% of cases [3]. Gram-negative bacilli and Gram-positive cocci are the most known bacterial, and *Aspergillus* spp., *Candida albicans*, and *Cryptococcus neoformans* are the primary fungal agents contributing to NIs. According to shreds of evidence, viruses may also contribute to some outbreaks [2, 4]. The infection rate in elderly patients, chemotherapy recipients, and patients with underlying diseases is higher than in healthy individuals [5]. Typically, 5-10% of patients in the ICU contract anywhere 1-5 types of NIs. Urinary tract infections (UTIs), surgical-site infections (SSIs), bloodstream

infections (BSI), and pneumonia are the most broadly categorized types of NIs by the Centers for Disease Control and Prevention (CDC), which are involved in more than 80% of the cases. A hospitalized patient is more vulnerable to various microorganisms, notably bacteria. Alongside other Gram-positive and Gram-negative bacteria, *S. aureus* is an important cause of BSI, pneumonia, and SSI. Pulmonary infections are associated with *A. baumannii*, *L. pneumophila*, and *Pseudomonas aeruginosa*. The burn wards are colonized dominantly by *P. aeruginosa* and Methicillin-resistant *Staphylococcus aureus* (MRSA). Gram-negative bacilli contribute to all NIs with a certain proportion. The prevalence rate and involved tissues have been inserted in Table 1 [6-14]. NIs or health-care associated infections can be transmitted readily to non-patients in hospitals. The most well-known cases are included lower respiratory tract infections, lung abscess or empyema, bone and joint infections,

cardiovascular infection, central nervous systems infection, and reproductive tract infections [15]. Approximately, 70% of infections caused by microorganisms are resistant to one or more antibiotic classes. The emergence of resistance is a crisis rooted in the indiscriminate prescription of antibiotics [16, 17]. Infections in the surgery wards are also challenging, with a third of patients contracting skin or wound infections post-surgery. The role of Gram-negative bacteria is prominent in comparison to the Gram-positives in these types of infections [7, 18]. Out of every 1000 hospitalized patients, seven are afflicted by *P. aeruginosa* infections, most often in burn wards. Children and elderly patients are at a greater risk of developing such infections [19]. The most remarkable consequences are prolonged

hospitalization and economic losses [20]. Knowledge of the origin of causative agents and their transmission route is crucial to preventing NIs. [21]. An ongoing debate is the relative role of aerosol transmission in the hospital setting, especially in vulnerable groups such as children and immunocompromised patients. Studies on medical settings and procedures or equipment relevant to increased risks of aerosol generation are required to prevent and control nosocomial infections via the aerosol route [22]. Due to the importance of NIs, in the realm of health and economics, here, we review the essential features of NIs, particularly the considerable role of bacteria and antibiotic resistance, which is the main challenge in the treatment procedure.

Table 1. The main bacterial causatives in common NIs and their prevalence.

Infection	Involved bacteria	Prevalence
UTI	<i>Enterococcus</i> spp., <i>S. aureus</i> , <i>E. coli</i> , <i>Klebsiella pneumoniae</i>	42%
SSI	Gram-negative organisms, <i>S. aureus</i>	20%
BSI	coagulase-negative <i>Staphylococci</i> (CONS), <i>S. aureus</i> , <i>Enterococci</i> , Aerobic Gram-negative bacilli	5-10%
Pneumonia	<i>P.aeruginosa</i> , <i>Serratia marcescens</i> , <i>S. aureus</i> , <i>Klebsiella</i> spp., <i>Streptococcus pneumoniae</i> , <i>Acinetobacter</i> spp., <i>Enterobacter</i> spp., <i>E. coli</i> , <i>Enterococcus</i> spp., <i>Stenotrophomonas maltophilia</i>	15-20%
Miscellaneous organs	All mentioned bacteria	16%

Bacteria

The role of bacteria in the NIs is significant due to the considerable proportion and side consequences [3]. Here, we aimed to discuss the more well-known bacterial cases.

Enterobacteriaceae. *Enterobacteriaceae*, a heterogeneous group of Gram-negative bacilli, are considered the most critical causative bacterial agents of NIs [23, 24]. All members of this family may cause BSI, abdominal infections, and peritonitis. They are found mainly in the different hospital wards, particularly in the ICU [25, 26]. *Enterobacter* spp. are the primary etiologic agents in nosocomial pneumonia [27]. Vancomycin-resistant *Enterococcus* (VRE) is one of the most well-known examples. The infections caused by these bacteria lead to extended hospitalization and mortality rates [28]. The members of this genus are inherently resistant to aminopenicillins, cefazolin, and cefoxitin via producing chromosomal AmpC beta-lactamase enzymes [29]. The presence of VRE in ICU and oncology-hematology wards is a medical challenge, and management of the treatment of colonized and infected patients and VRE identification must be considered an emergency action [30]. Based on recent analysis, nosocomial VRE infections increase hospital costs compared to VSE (Vancomycin Sensitive *Enterococcus*) infections. Therefore, implementing control measures to prevent VRE transmission seems to be necessary [31]. Overall, the emergence of carbapenem-resistant *Enterobacteriaceae* (CRE) and beta-lactamase-producing types is a significant medical concern to physicians and clinical microbiologists due to the limited available antimicrobials choice [32, 33]. One of the most important bacteria in pediatric wards is extended-

spectrum beta-lactamases (ESBLs)-producing *E. coli* [34]. The resistance rate to imipenem in nosocomial *E. coli* isolates is over 90%, and ESBL-producing *E. coli* in hospitals is a significant challenge [35]. Also, *E. coli* contributes to nosocomial UTI incidence [36].

Klebsiella spp., especially *Klebsiella pneumoniae*, is another major cause of nosocomial UTI [36]. The rapid spread of this pathogen in hospitals underscores its importance and the occurrence of NIs [6]. Due to antibiotic resistance, particularly to carbapenems, managing the *K. pneumoniae* infections is more complicated. In addition to UTIs, this bacterium accounts for other NIs such as septicemia [14]. Recently, a high carbapenem-resistant *K. pneumoniae* incidence in patients with invasive infections occurred in Europe and Asia [37, 38].

Serratia marcescens is an opportunistic nosocomial pathogen that contributes to UTIs with mild to severe symptoms. This bacterium also causes respiratory and biliary tract infections, peritonitis, wound infections, and intravenous catheter-related infections [39]. There is also a worrisome emergence of drug resistance related to this pathogen by various mechanisms [40, 41]. Resistance to penicillins in *Serratia* spp. is over 90%, and the alarming fatality rate associated with *S. marcescens* is ~41.6 % [42].

Pseudomonas aeruginosa. *P. aeruginosa* is a difficult-to-treat pathogen and is abundantly found in hospital equipment. Besides infections in immunocompromised patients, this extremely virulent pathogen may cause pulmonary infections in cystic fibrosis patients [43, 44]. It

accounts for up to 11% of NIs, with a high ability to colonize a broad range of organs [13]. Ventilator-associated pneumonia is a significant NI caused by *P. aeruginosa* [45]. This infection commonly occurs during extracorporeal membrane oxygenation, frequently by multidrug-resistant (MDR) microorganisms, resulting in a poor prognosis [46]. This bacterium also causes life-threatening infections in burn wards [47]. Currently, *P. aeruginosa* has a leading role in hospital-acquired bacteremia, accounting for ~4% of all cases and the third leading cause of Gram-negative BSI [48]. *Pseudomonas* spp. exhibits a high level of resistance to most antibiotics, resulting in high mortality rates [49]. One of the antibiotic resistance pathways in this pathogen is the active efflux pump and change in porin channel expression. The most important of these pumps belongs to the RND (resistance nodulation cell division) family. In addition to a significant intrinsic resistance to antibiotics, *P. aeruginosa* can acquire resistance utilizing chromosomal mutations and acquiring antibiotic resistance genes [50-52]. Based on previous data, *P. aeruginosa* isolates from the respiratory tract are resistant to imipenem [53]. The mortality rates reach 40-50% in patients with burn wounds infected with *P. aeruginosa*, which are very difficult to treat. Preventing burn wound infections with this microorganism is much more preferable and cost-effective than treatment after acquired infections [54, 55].

***Acinetobacter baumannii*.** *A. baumannii*, a Gram-negative and nonmotile microorganism, is the significant cause of NIs. MDR *A. baumannii* is increasingly associated with various epidemics and has become a significant concern in various hospitals worldwide [56]. Bacteremia, surgical wounds, and respiratory tract infections are other NIs caused by this bacterium [57]. In inpatient facilities, *A. baumannii* is also a problematic microorganism, particularly in the ICU [58]. This opportunistic bacterium may cause infections in immunocompromised individuals with circulatory/respiratory system insufficiency and is more resistant to antibiotics than *Enterobacteriaceae* members. Therefore, it must be considered a severe clinical threat to patients and health care [59]. Imipenem is one of the best choices for treating pneumonia caused by this bacterium [60]. *A. baumannii* is more commonly isolated from ventilators than *P. aeruginosa*; however, it is not the leading cause of pneumonia associated with ventilators and BSI. The mortality rate of infections caused by this bacterium is ~34% [61]. A large group of hydrolyzing enzymes, such as MBLs, IMP, VIM, and class D carbapenemase, are produced by resistant isolates. Porin channels are the primary resistance caused by beta-lactams. Furthermore, recent investigations revealed that the loss of outer membrane proteins is also involved in the resistance to beta-lactams [50, 62].

***Staphylococcus aureus*.** *S. aureus* is a major human pathogen in healthcare-associated infections. It has severe outcomes in endocarditis and prosthetic device infections

[63-65]. *S. aureus* strains, in particular, MRSA, are one of the most common causes of hospital-acquired infections with increased prevalence over the past decade [66]. Hospital burn wards are usually considered a source of MRSA infections [67]. MRSA is a global health threat and is believed to have emerged due to excessive antibiotic prescription patterns [68]. According to extensive reviews, *S. aureus* is mostly isolated from equipment in hospitals [66]. This organism may colonize a wide variety of body tissues from the skin to the respiratory tract, and the status of the patient's immunity system may exacerbate the infections [69, 70]. The mortality rate of SSIs reaches up to 6.7% [71] as the second most important NIs, which affects approximately 2-5% of surgery-subjected patients [2]. Other infections, including pneumonia, mediastinitis, and UTI, may also be caused by this pathogen [72]. Resistance to β -lactam antibiotics makes the treatment procedure more complex [63].

Importance of antibiotic resistance in nosocomial bacteria. NIs have been elevating due to excessive and improper use of broad-spectrum antibiotics, particularly in healthcare settings [13]. Patients with underlying diseases and immunocompromised individuals are more vulnerable to the complications of antibiotic-resistant microorganisms [73]. Every five minutes in South-East Asia, one child dies due to a lack of effective antibiotics [2]. This resistance is evident in the *Enterobacteriaceae* and *Pseudomonas* spp. [74, 75]. The importance of antibiotic resistance as a medical issue is not elucidated completely for all microorganisms and associated infections; resistance determinants have a diverse origin [64, 76-78]. Environmental factors in antibiotic resistance, including water and food contamination, are significant, especially in Gram-negative bacteria [65, 79]. Hospitals also provide optimal conditions for microorganisms to develop resistance to effective antibiotics [53].

Attention to resistance may provide more desirable results and success if directed to decrease the NIs incidence [80].

Viral NIs

Viral NIs appear more in respiratory and gastrointestinal forms in hospitalized individuals, particularly immunocompromised patients [81].

Viral respiratory NIs. Elderly patients and hospitalized children in pediatric wards are more exposed to viral NIs than others. Respiratory syncytial virus (RSV) is directly related to NIs in pediatric wards [82]. RSV infections account for high mortality rates in children with an underlying disease, and in elderly patients, it causes pneumonia and increases cardiac manifestations [83]. It is difficult to distinguish viral cases of pneumonia from bacterial ones; therefore, the exact details of viral cases are not accurate. However, specific

viral diagnosis methods identified RSV and influenza viruses as the cause of pneumonia in the ICU wards [84]. Hospitalized patients' most critical respiratory pathogens are adenoviruses and influenza type B virus [85]. The viral respiratory tract infections (RTI) in Germany in the winter of 2012-2013 reached the highest observed during the past decade [86]. Nosocomial influenza outbreaks are frequent, particularly among the frail groups, while the control remains challenging. However, the actual statistics are underestimated [87, 88]. Vaccinating the staff could be the primary strategy to reduce the consequences of nosocomial influenza infections in cancerous patients [89]. The human coronavirus contributes to RTI in pediatric wards, which might affect the ward staff [90, 91]. A pandemic of this virus in 2019 brought many changes worldwide, including lifestyle and compliance with health regulations [91]. This pandemic has also placed a massive burden on healthcare providers and hospitals worldwide. Several reports indicated nosocomial SARS-CoV-2 (severe acute respiratory syndrome-Corona Virus-2) outbreaks, with 60% mortality rates; however, it can vary in different countries [92-94]. The reports indicate that SARS-CoV-2 is not spread only by airbornes, and other transmission routes are also involved. Nosocomial transmissions can be prevented by rigorous basic control measures, such as wearing surgical masks, hand hygiene, and environmental hygiene [95].

Viral gastrointestinal Nis. Acute NIs of the gastrointestinal tract are among the most common infectious diseases in hospitals [96]. A point-prevalence survey in 2011 estimated the nosocomial gastrointestinal infections rate at 17.1%; however, it varies in different regions [15]. Healthcare-associated gastroenteritis outbreaks are prevalent and increasingly recognized in clinics; however, detailed knowledge of epidemiology is lacking [97]. Rotavirus, norovirus, astrovirus, and adenovirus are the four significant viruses contributing to nosocomial gastroenteritis. Of note is that the role of rotavirus, especially in the outbreak of diarrhea in pediatric wards, is highly significant [98, 99]. The role of astrovirus is also remarkable in diarrheic children. The majority of nosocomial diarrhea causative viruses are acquired through the oral-fecal route. The prevention process primarily relies on controlling virus transmission, such as frequent handwashing with soap and water [100]. Advanced molecular diagnostic methods can recognize many more nosocomial viral infections previously unreported. Such infections include norovirus gastroenteritis [101].

Viral NIs in immunocompromised patients. Immunosuppressed and elderly patients with underlying chronic diseases are at a higher risk of viral NIs [86]. HIV-infected hospitalized patients, including those whose CD4 lymphocyte count is less than a threshold, are more susceptible to pulmonary infections than other groups [102]. Some studies revealed that HIV-infected patients diagnosed with HSV infection and non-Hodgkin's

lymphoma are more predisposed to contract NIs [103]. There is a possibility of transmission of human T-cell lymphotropic virus III (HTLV III) among the hospital staff due to needle-stick errors. This virus is prevalent among HIV-infected patients [104]. Due to limited therapeutic options to deal with viral infections, the emergence of antiviral resistance is a more serious problem compared to antibiotic resistance to bacteria. Acyclovir and ganciclovir-resistant herpes isolates pose a substantial threat to immunocompromised patients, especially those with HIV [105].

Nosocomial HBV (Hepatitis B Virus) infection has been traditionally relevant to the transfusion of contaminated blood and its products. Multiple HBV outbreaks have been observed in pediatric oncology inpatient wards [106]. Numerous factors contribute to the increased risk of infection in cancer patients, including immunodeficiency, underlying malignancy, and cytostatic chemotherapy [107]. Vaccination programs and ongoing HBV screening in oncology and pediatric hematology wards must become the standard of care [106, 108]. The HCV (Hepatitis C virus) is another common nosocomial pathogen transmitted through blood transfusion, dialysis, and kidney transplantation in hospital wards (Fig. 1) [109]. The hospital staff contributes to the dissemination of this virus [110]. Transmission of viral pathogens through the staff is an evident challenge in hospitals. The most remarkable example points out one of the most dangerous viral infections, Ebola, which affected healthcare workers in the 2014 outbreak and prepared the conditions for spreading the virus into the community [111].

Fungal NIs

Numerous fungal outbreaks have occurred in hospital settings which are considered a serious threat to immunocompromised individuals. Construction and renovation activities lead to severe dust contamination and disperse large amounts of fungal spores. These activities are an independent risk factor for invasive fungal infections [112]. The advent of new technologies in surgery, bone marrow, and organ transplantation plays a significant role in the high incidence of fungal NIs. Immunocompromised patients, particularly HIV-infected individuals, cancerous patients, and premature neonates, are more vulnerable to fungal pathogens, presenting the extreme severity of these infections [113, 114]. Additionally, hospitalized patients under chemotherapy who suffer from neutropenia and malnutrition are more likely to contract hospital-acquired fungal infections [113]. *C. albicans*, as a nosocomial pathogen with the ability to survive on surfaces for up to 4 months, is the most well-known hospital fungal agent [115]. There is a higher chance of candidemia in immunocompromised patients (Fig. 2) [116]. According to some reports, *Candida* spp. especially *C. albicans* can cause local and systemic infections in hospitalized patients, the most

prevalent mucosal NI [117]. Also, some BSI cases might be induced by *C. albicans* [118]. *C. auris* is a multidrug-resistant yeast that has emerged to cause nosocomial outbreaks in several countries over the past three years. This microorganism causes serious invasive infections and probably spreads among patients. It can survive for months on hospital equipment [119]. Some reports highlight ongoing challenges due to misidentification of this healthcare-associated fungal pathogen and remarkable mortality rates [120]. Other

fungal agents have a significant role in nosocomial pulmonary infections, such as *Cryptococcus* spp. and *Aspergillus* spp., causing high mortality rates [121]. *Aspergillus* spp. can infect the lung and sinus maxillaries in frail patients [112]. Mucorales, *Fusarium* spp., and other molds may also contribute to fungal infections in hospital wards [122]. In addition to the species mentioned above, *Trichosporon* spp., *Fusarium* spp., and *Mucor* spp. are the most isolated fungal agents in ICUs and transplant wards [123].




Fig. 1. Transmission routes of HCV and HBV in hospital wards. The HCV as a minor member of *Flaviviridae* is usually transmitted via blood transfusion from an HCV-infected patient. HBV can be transmitted readily through blood and related products in hospitals.

Impact of NIs on economy and society (how to deal with them)

The magnitude of hospital-acquired infections depends on the hospital area, hygiene circumstances, and hospitalization period. One of the most severe problems in dealing with these infections is antibiotic resistance [124]. The role of NIs in the mortality rate of hospitalized patients is tremendous. Even though the high morbidity rate in women is high, more mortality is observed in men [125]. Economic losses due to NIs consist of two critical aspects; increased treatment costs and extended hospitalization [126]. More than 7 million people in the United States see a physician due to the nosocomial UTI every year [127]. Apart from economic losses, which affect public health financially, extended hospitalization is another significant challenge (Table 2) [128-130].

With adequate staff training and observance of prevention and control regulations, the transmission of pathogenic agents associated with Nis can be controlled in hospitals and clinical centers [82]. Based on other published statistics, NIs affect more than 2 million people annually in the United States, with 90000 cases leading to death [16]. The concerns remain since resistant *E. coli* and *S. aureus* are the most commonly isolated bacteria from hospitalized patients. The role of microbiology laboratories will be momentous in identifying these pathogens and controlling them [53]. The primary measures to control NIs include several regulations which can effectively reduce these infections by up to 32% (Fig. 3) [16, 55, 131-133].

Table 2. Economic loss and annually estimated mortality rate associated with NIs in the United States.

Type of nosocomial infection	Economic loss per case	Mortality rate	Excess Hospitalization
Urinary tract infections	558-593\$	30.8%	1-4 days
Surgical site infections	2.734\$	89%	7-8.2 days
Bloodstream infections	3.061-40000\$	23.8-50%	7-21 days
Pneumonia	4.947\$	14.8-71%	6.8-30 days




Fig. 2. NIs in immunocompromised patients. These individuals are affected readily by various microorganisms compared to healthy individuals and present more significant clinical symptoms.




Fig. 3. Some recommended strategies by WHO for controlling NIs and reducing their incidence.

Conclusion

According to the published literature related to NIs, bacteria, viruses, and fungi have a significant role in the

hospital infections incidence. Viruses and fungi may contribute to NIs, depending on the conditions. Viral infections mainly affect immunocompromised patients and pediatric wards. Immunocompromised individuals,

especially HIV-infected patients and organ recipients, are the most vulnerable population groups. Bacteria, viruses, and fungi can cause coinfections, and overall, viral NIs have severe occurrence. The morbidity and mortality rate is variable in different age groups. Due to the emergence of antibiotic resistance, limited therapeutic options pose a severe health concern. Every microorganism presents different rates of antibiotic resistance, depending on multiple factors.

More studies on the impact of drug resistance in treating infectious diseases are required due to its impact on the health care system. It is urgent to implement practical solutions in hospitals and clinical centers to deal with these infections.

Concisely, NIs occur worldwide, and patients, communities, and health officials are involved in these infections directly or indirectly. Therefore, knowledge of the NIs must be updated continuously.

NIs surveillance is relevant to decreased infection rates, though randomized controlled trials require proving the influential role of surveillance. Decreased NIs incidences could shorten hospitalization time and reduce the financial burden. Therefore, hospitals may consider performing NIs surveillance systems according to their conditions. Besides the known nosocomial pathogens, emerging pathogenic agents are another serious issue that must be considered regarding resistance, treatment, and other medical aspects.

ACKNOWLEDGMENT

The authors would like to thank the Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences for providing the expertise that greatly assisted.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest associated with this manuscript.

REFERENCES

1. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. *Infect Control Hosp Epidemiol*. 2002; 23 (3): 137-40.
2. Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. *Asian Pac J Trop Biomed*. 2017; 7 (5): 478-82.
3. Vonberg R-P, Weitzel-Kage D, Behnke M, Gastmeier P. Worldwide Outbreak Database: the largest collection of nosocomial outbreaks. *Infection*. 2011; 39 (1): 29-34.
4. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, et al. Update on bacterial nosocomial infections. *Eur Rev Med Pharmacol Sci*. 2012; 16 (8): 1039-44.
5. Khazaei S, Khazaei S, Ayubi E. Importance of Prevention and Control of Nosocomial Infections in Iran. *Iran J Public Health*. 2018; 47 (2): 307-8.

6. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev*. 1998; 11 (4): 589-603.
7. Brachman PS, Dan BB, Haley RW, Hooton TM, Garner JS, Allen JR. Nosocomial surgical infections: incidence and cost. *Surg Clin North Am*. 1980; 60 (1): 15-25.
8. Nichols R.L. Preventing surgical site infections: a surgeon's perspective. *Emerg Infect Dis*. 2011; 7 (2): 220-4.
9. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis*. 2004; 39 (3): 309-17.
10. Salata RA, Lederman MM, Shlaes DM, Jacobs MR, Eckstein E, Twardy D, et al. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. *Am Rev Respir Dis*. 1987; 135 (2): 426-32.
11. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. *Am J Respir Crit Care Med*. 2000; 161 (3): 753-62.
12. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. *Diagn Microbiol Infect Dis*. 2005; 52 (3): 187-93.
13. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. *Asian Pac J Trop Biomed*. 2015; 5 (7): 509-14.
14. Pitout, JDD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*: a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother*. 2015; 59 (10): 5873-84.
15. Sikora A, Zahra F. Nosocomial infections. *StatPearls* [Internet], 2021.
16. Burke JP. Infection control--a problem for patient safety. *N Engl J Med*. 2003; 348 (7): 651-6.
17. Klevens RM, Edwards JR, Richards Jr CL, Horan TC, Gaynes RP, Pollock DA, et al. Estimating healthcare-associated infections and deaths in US hospitals, 2002. *Public Health Rep*. 2007; 122 (2): 160-6.
18. Leylabadlo HE, Samadi Kafil H, Aghazadeh M, Hazratian T. Nosocomial oral myiasis in ICU patients: occurrence of three sequential cases. *GMS Hyg Infect Control*. 2015; 10.
19. Bennett JV. Nosocomial infections due to *Pseudomonas*. *J Infect Dis*. 1974; 130 (Supplement): 4-7.
20. Mendiola-So M, Larson RE, Vernier D. A systematic review of whirlpool as an adjunctive treatment for cellulitis. *Wound Med*. 2017; 19: 47-74.
21. Mardaneh J, Soltan Dallal MM. Isolation and identification *Enterobacter asburiae* from consumed powdered infant formula milk (PIF) in the neonatal intensive care unit (NICU). *Acta Med Iran*. 2016; 54 (1): 39-43.

22. Bing-Yuanab, Yun-Hui Zhangb, Nancy H.L.Leungc, Benjamin J.Cowlingc, Zi-Feng Yang. Role of viral bioaerosols in nosocomial infections and measures for prevention and control. *J Aerosol Sci.* 2018; 117: 200-11.
23. Lax S, Gilbert JA. Hospital-associated microbiota and implications for nosocomial infections. *Trends Mol Med.* 2015; 21 (7): 427-32.
24. Vasoo S, Barreto JN, Tosh PK. Emerging issues in Gram-negative bacterial resistance: an update for the practicing clinician. in *Mayo Clinic Proceedings.* 2015; 90 (3): 395-403..
25. Harris PNA, Tambyah PA, Paterson DL. β -lactam and β -lactamase inhibitor combinations in the treatment of extended-spectrum β -lactamase producing *Enterobacteriaceae*: time for a reappraisal in the era of few antibiotic options? *Lancet Infect Dis.* 2015; 15 (4): 475-85.
26. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. *Clin Infect Dis.* 2005; 41 (6): 848-54.
27. Torres A, Zhong N, Pacht J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. *Lancet Infect Dis.* 2018; 18 (3): 285-95.
28. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect Drug Resist.* 2015; 8: 217-30.
29. Paterson DL. Resistance in Gram-negative bacteria: *Enterobacteriaceae*. *Am J Infect.* 2006; 119 (6 Suppl 1): S20-8.
30. Devrim F, Gülfidan G, Gözmen S, Demirağ B, Oymak Y, Yaman Y, et al. Comparison of the BD GeneOhm VanR assay and a chromogenic agar-based culture method in screening for vancomycin-resistant enterococci in rectal specimens of pediatric hematology-oncology patients. *Turk J Pediatr Dis.* 2015; 57 (2): 161-6.
31. Puchter L, Chaberny IF, Schwab F, Vonberg RF, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. *Antimicrob Resist Infect Control.* 2018; 7 (1): 1.
32. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, Chen H, et al. Risk factors and clinical outcomes for carbapenem-resistant *Enterobacteriaceae* nosocomial infections. *Eur J Clin Microbiol.* 2016; 35 (10): 1679-89.
33. Ebrahimzadeh Leylabadlo H, Poursak T, Zahedi Bialvaei A, Aghazadeh M, Asgharzadeh M, Samadi Kafil, et al. Extended-spectrum beta-lactamase producing Gram negative bacteria in Iran: a review. *Afr J Infect Dis.* 2017; 11 (2): 39-53.
34. Rezai MS, Salehifar E, Rafiei A, Langae T, Rafati M, Shafahi K, et al. Characterization of multidrug resistant extended-spectrum beta-lactamase-producing *Escherichia coli* among uropathogens of pediatrics in North of Iran. *Biomed Res Int.* 2015; 309478.
35. Anago E, Ayi-Fanou L, Akpovi CD, Hounkpe WB, Tchibozo MAD, Bankole HS, et al. Antibiotic resistance and genotype of beta-lactamase producing *Escherichia coli* in nosocomial infections in Cotonou, Benin. *Ann Clin Microbiol.* 2015; 14 (1): 5.
36. Cho YH, Jung S II, Chung HC, Yu HS, Hwang EC, Kim SO, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. *Int Urol Nephrol.* 2015; 47 (7): 1059-66.
37. Sotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, et al. Nosocomial transmission of carbapenem-resistant *Klebsiella pneumoniae* in an Italian university hospital: a molecular epidemiological study. *J Hosp Infect.* 2018; 99 (4): 413-8.
38. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu b, et al. Epidemiology of carbapenem-resistant *Enterobacteriaceae* infections: report from the China CRE Network. *Antimicrob Agents Chemother.* 2018; 62 (2): 1882-17.
39. Kim SB, Jeon YD, Kim JH, Kim JK, Ann HW, Choi H, et al. Risk factors for mortality in patients with *Serratia marcescens* bacteremia. *Yonsei Med J.* 2015; 56 (2): 348-54.
40. Maki DG, Hennekens CG, Phillips CW, Shaw WV, Bennett JV. Nosocomial urinary tract infection with *Serratia marcescens*: an epidemiologic study. *J Infect Dis.* 1973; 128 (5): 579-87.
41. Su, LH, Ou JT, Leu HS, Chiang PC, Chiu YP, Chia JH, et al. Extended epidemic of nosocomial urinary tract infections caused by *Serratia marcescens*. *J Clin Microbiol.* 2003; 41 (10): 4726-32.
42. Soltani J, Poorabbas B, Miri N, Mardaneh J. Health care associated infections, antibiotic resistance and clinical outcome: A surveillance study from Sanandaj, Iran. *World J Clin Cases.* 2016; 4 (3): 63-70.
43. Mitov I, Strateva T, Markova B. Prevalence of virulence genes among Bulgarian nosocomial and cystic fibrosis isolates of *Pseudomonas aeruginosa*. *Braz J Microbiol.* 2010; 41 (3): 588-95.
44. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2015; 59 (2): 1020-9.
45. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. *Intensive Care Med.* 2010; 36 (6): 971-8.
46. Grasselli G, Scaravilli V, Di Bella S, Biffi S, Bombino M, Patroniti N, et al. Nosocomial infections during extracorporeal membrane oxygenation: Incidence, etiology, and impact on patients' outcome. *Crit Care Med.* 2017; 45 (10): 1726-33.
47. Dai T, Gupta A, Huang YY, Yin R, Murray CK, Vrahas MS, et al. Blue light rescues mice from potentially fatal *Pseudomonas aeruginosa* burn infection: efficacy, safety, and mechanism of action. *Antimicrob Agents Chemother.* 2013; 57 (3): 1238-45.
48. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage *Pseudomonas aeruginosa* infections. *Drugs context.* 2018; 7: 212527.
49. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello L, Chastre J, et al. An international multicenter retrospective study

- of *Pseudomonas aeruginosa* nosocomial pneumonia: impact of multidrug resistance. *Crit Care*. 2015; 19 (1): 219.
50. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β -lactams in peril! *Curr Opin Microbiol*. 2005; 8 (5): 518-24.
 51. Van Eldere J. Multicentre surveillance of *Pseudomonas aeruginosa* susceptibility patterns in nosocomial infections. *J Antimicrob Chemother*. 2003; 51 (2): 347-52.
 52. Botelho J, Grosso F, Peixe L. Antibiotic resistance in *Pseudomonas aeruginosa*—Mechanisms, epidemiology and evolution. *Drug Resist Updat*. 2019; 44: 100640.
 53. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev*. 1993; 6 (4): 428-42.
 54. Lari AR, Alaghebandan R. Nosocomial infections in an Iranian burn care center. *Burns*. 2000; 26 (8): 737-40.
 55. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of *Pseudomonas aeruginosa* serotypes in burn wound infections and their resistance to antibiotics. *Burns*. 2002; 28 (4): 340-8.
 56. Almasaudi SB. *Acinetobacter* spp. as nosocomial pathogens: Epidemiology and resistance features. *Saudi J Biol Sci*. 2018; 25 (3): 586-96.
 57. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical features and treatment. *Clin Microbiol Infect*. 2002; 8 (11): 687-93.
 58. Gonzalez-Villoria AM Valverde-Garduno V. Antibiotic-resistant *Acinetobacter baumannii* increasing success remains a challenge as a nosocomial pathogen. *J Pathog*. 2016: 7318075.
 59. Sieniawski K, Kaczka K, Rucińska M, Gagis L, Pomorski L. *Acinetobacter baumannii* nosocomial infections. *Pol J Surg*. 2013; 85 (9): 483-90.
 60. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. *Clin Infect Dis*. 2003; 36 (9): 1111-8.
 61. Labarca JA, Costa Salles MJ, Seas C, Guzmán-Blanco M. Carbapenem resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in the nosocomial setting in Latin America. *Crit Rev Microbiol*. 2016; 42 (2): 276-92.
 62. Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant *Acinetobacter baumannii*. *Int J Infect Dis*. 2015; 38: 32-5.
 63. Steven Y C Tong, Joshua S Davis, Emily Eichenberger, Thomas L Holland, Vance G Fowler Jr. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*. 2015; 28 (3): 603-61.
 64. Hasani A, Asadi Faezi N, Ahangarzadeh Rezaee M, Sheykhsaran E, Darabi N, Ebrahimzadeh Leylabadlo H. Determination of Antimicrobial Resistance Patterns in Bloodstream Infections-Isolated Bacteria From a University Tertiary Hospital Patients. *Int J Enteric Pathog*. 2019; 7 (2): 49-54.
 65. Abad HEK, Sadeghi J, Aghazadeh M, Ahangarzadeh Rezaee M, Samadi Kafil H, Ahangar Oskouee M, et al. Frequency of *fnbA*, *fnbB*, *hla* and *cna* genes in *Staphylococcus aureus* isolates obtained from blood cultures and their antimicrobial susceptibility pattern in Tabriz, Iran. *Arch Pharm Pract*. 2020; 11 (S1): 137-43.
 66. Zorgani A, Abofayed A, Glija A, Albarbar A, Hanish S. Prevalence of device-associated Nosocomial infections caused by Gram-negative bacteria in a trauma intensive care unit in Libya. *Oman Med J*. 2015; 30 (4): 270-5.
 67. Boyce JM, White RL, Causey WA, Lockwood WR. Burn units as a source of methicillin-resistant *Staphylococcus aureus* infections. *Jama*. 1983; 249 (20): 2803-7.
 68. Graffunder EM, Venezia R.A. Risk factors associated with nosocomial methicillin-resistant *Staphylococcus aureus* (MRSA) infection including previous use of antimicrobials. *Antimicrob Chemother*. 2002; 49 (6): 999-1005.
 69. Valaperta R, Rosa Tejada M, Frigerio M, Moroni A, Ciulla E, Cioffi S, et al. *Staphylococcus aureus* nosocomial infections: the role of a rapid and low-cost characterization for the establishment of a surveillance system. *New Microbiol*. 2010; 33 (3): 223-32.
 70. M Melzer, S J Eykyn, W R Gransden, S Chinn. Is methicillin-resistant *Staphylococcus aureus* more virulent than methicillin-susceptible *S. aureus*? A comparative cohort study of British patients with nosocomial infection and bacteremia. *Clin Infect Dis*. 2003; 37 (11): 1453-60.
 71. John J Engemann, Yehuda Carmeli, Sara E Cosgrove, Vance G Fowler, Melissa Z Bronstein, Sharon L Trivette, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with *Staphylococcus aureus* surgical site infection. *Clin Infect Dis*. 2003; 36 (5): 592-8.
 72. G Lina, Y Piémont, F Godail-Gamot, M Bes, M O Peter, V Gauduchon., et al. Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis*. 1999; 29 (5): 1128-32.
 73. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant *Staphylococcus aureus*, *enterococcus*, Gram-negative bacilli, *Clostridium difficile*, and *Candida*. *Ann Intern Med*. 2002; 136 (11): 834-44.
 74. Carmeli Y, Armstrong J, J Laud P, Newell P, Stone S, Wardman, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant *Enterobacteriaceae* and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. *Lancet Infect Dis*. 2016; 16 (6): 661-73.
 75. Sheykhsaran E, Bannazadeh Baghi H, Soroush Barhaghi MH, Alizadeh N, Memar MY et al. The rate of resistance to tetracyclines and distribution of *tetA*, *tetB*, *tetC*, *tetD*, *tetE*, *tetG*, *tetJ* and *tetY* genes in *Enterobacteriaceae* isolated from Azerbaijan, Iran during 2017. *J Physiol Pharmacol*. 2018; 22 (3): 205-12.
 76. Bin Zaman S, Awlad Hussain M, Nye R, Mehta V, Taib Mamun K, Hossain N. A review on antibiotic resistance: alarm bells are ringing. *Cureus*. 2017; 9 (6): e1403.

77. Sheykhsaran E, Baghi Hossein B, Soroush Mohammad H, Ghotaslou R. An overview of tetracyclines and related resistance mechanisms. *Rev Med Microbiol.* 2019; 30 (1): 69-75.
78. Lalehzadeh A, Soroush MH, Sadeghi J, Ahangarzadeh Rezaee M, Pirzadeh T, Yeganeh Sefidan F, et al. Determination of fosfomycin resistant *Enterobacteriaceae* in isolates and frequency of fos genes in Tabriz Hospitals during 2018. *J Biochem Tech.* 2019; 10 (2): 143-8.
79. Economou V, P Gousia. Agriculture and food animals as a source of antimicrobial-resistant bacteria. *Infect Drug Resist.* 2015; 8: 49-61.
80. Rachel B. Slayton, Damon Toth, Bruce Y. Lee, Windy Tanner, Sarah M. Bartsch, Karim Khader, et al. Vital signs: estimated effects of a coordinated approach for action to reduce antibiotic-resistant infections in health care facilities - United States. *MMWR Morb Mortal Wkly Rep.* 2015; 64 (30): 826-31.
81. Wang Y, Li X, Ge T, Xiao Y, Liao Y, Cui Y, et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. *Medicine.* 2016; 95 (31): e4509.
82. Aitken C, DJ Jeffries. Nosocomial spread of viral disease. *Clin Microbiol Rev.* 2001; 14 (3): 528-46.
83. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. *Clin Infect Dis.* 2000; 31 (2): 590-6.
84. D L George. Nosocomial viral pneumonia in the intensive care unit. *Clin Chest Med.* 1995; 16 (1): 29-44.
85. Faezi NA, Zahedi Bialvaei A, Ebrahimzadeh Leylabadlo H, Soleimani H, Yousefi M, Samadi Kafil H. Viral infections in patients with acute respiratory infection in Northwest of Iran. *Mol Gen Microbiol Virol.* 2016; 31 (3): 163-7.
86. Lehnert N, Tabatabai J, Prifert CH, Wedde M, Puthenparambil J, Weissbrich B, et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. *PLoS One.* 2016; 11 (2): e0148258.
87. Vanhems P, T Bénet, E Munier-Marion. Nosocomial influenza: encouraging insights and future challenges. *Curr Opin Infect Dis.* 2016; 29 (4): 366-72.
88. Sheykhsaran E, N Hemmat, HB Baghi. Influenza A virus and related secondary bacterial infections. *Rev Med Microbiol.* 2018; 29: 205-11
89. Frenzel E, Chemaly RF, Ariza-Heredia E, Jiang Y, P Shah D, Thomas G, et al. Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. *Am J Infect Control.* 2016; 44 (9): 1016-21.
90. A Gagneur, J Sizun, S Vallet, M C Legr, B Picard, P J Talbot. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. *J Hosp Infect.* 2002; 51 (1): 59-64.
91. Sarkesh A, Daei Sorkhabi A, Sheykhsaran E, Alinezhad F, Mohammadzadeh N, Hemmat N, et al. Extrapulmonary clinical manifestations in COVID-19 patients. *Am J Trop Med.* 2020; 103 (5): 1783-96.
92. Abbas M, Nunes TR, Martischang R, Zingg W, Iten I, Pittet D, et al. Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. *Antimicrob Resist Infect Control.* 2021; 10 (1): 1-13.
93. Oke J, C Heneghan. Global COVID-19 case fatality rates-CEBM. URL <https://www.cebim.net/covid-19/global-covid-19-case-fatality-rates> [accessed 29 March 2020], 2020.
94. Quah P, A Li, J Phua. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. *Critic Care.* 2020; 24 (1): 285.
95. S C Y Wong, R T-S Kwong, T C Wu, J W M Chan, M Y Chu, S Y Lee, et al. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong. *J Hosp Infect.* 2020; 105 (2): 119-27.
96. Zboromyrska Y, J Vila. Advanced PCR-based molecular diagnosis of gastrointestinal infections: challenges and opportunities. *Expert Rev Mol Diagn.* 2016; 16 (6): 631-40.
97. Ben A Lopman, Mark H Reacher, Ian B Vipond, Dawn Hill, Christine Perry, Tracey Halladay, et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002–2003. *Emerg Infect Dis.* 2004. 10 (10): 1827-34.
98. Adissa Tran, Déborah Talmud, Benoît Lejeune, Nicolas Jovenin, Fanny Renois, Christopher Payan, et al. Prevalence of rotavirus, adenovirus, norovirus, and astrovirus infections and coinfections among hospitalized children in northern France. *J Clin Microbiol.* 2010; 48 (5): 1943-6.
99. Olivier Gleizes, Ulrich Desselberger, Vladimir Tatochenko, Carlos Rodrigo, Nuran Salman, Zsolt Mezner. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. *Pediatr Infect Dis J.* 2006; 25 (1): 12-21.
100. Diem-Lan Vu, Albert Bosch, Rosa M Pintó, Susana Guix. Epidemiology of classic and novel human astrovirus: gastroenteritis and beyond. *Viruses.* 2017; 9 (2): 33.
101. Breathnach AS. Nosocomial infections and infection control. *Medicine.* 2013; 41 (11): 649-53.
102. G Di Perri, M Cruciani, M C Danzi, R Luzzati, G De Checchi, M Malena, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. *Lancet.* 1989; 334 (8678-8679): 1502-4.
103. U Frank, F D Daschner, G Schulgen, J Mills. Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. *Clin Infect Dis.* 1997; 25 (2): 318-20.
104. D K Henderson, A J Saah, B J Zak, R A Kaslow, H C Lane, T Folks, et al., Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). *N Engl J Med.* 1985; 312 (1): 644-7.
105. Nicolas Ponroy, Aline Taveira, Nicolas J Mueller, Anne-Laure Millard. Statins demonstrate a broad anti-cytomegalovirus activity *in vitro* in ganciclovir-susceptible and resistant strains. *J Med Virol.* 2015; 87 (1): 141-53.
106. Ané Büchner, Nicolette M Du Plessis, David T Reynders, Fareed E Omar, Simnikiwe H Mayaphi, Ahmad F Haeri Mazanderani, et al. Nosocomial outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South Africa: Epidemiological investigation and measures to prevent

- further transmission. *Pediatr Blood Cancer*. 2015; 62 (11): 1914-19.
107. Hwang JP, HA Torres. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. *Curr Opin Infect Dis*. 2018; 31 (6): 535-41.
 108. Uga Dumpis, Zanna Kovalova, Juris Jansons, Liene Cupane, Irina Sominskaya, Marija Michailova, et al. An outbreak of HBV and HCV infection in a pediatric oncology ward: epidemiological investigations and prevention of further spread. *J Med Virol*. 2003; 69 (3): 331-8.
 109. P M Schneeberger, I Keur, A M van Loon, D Mortier, K O de Coul, A V van Haperen, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. *J Infect Dis*. 2000; 182 (5): 1291-9.
 110. N Petrosillo, P Gilli, D Serraino, P Dentico, A Mele, P Ragni, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. *Am J Kidney Dis*. 2001; 37 (5): 1004-10.
 111. Shears P, T O'Dempsey. Ebola virus disease in Africa: epidemiology and nosocomial transmission. *J Hosp Infect*. 2015; 90 (1): 1-9.
 112. Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. *Clin Infect Dis*. 2015; 61 (3): 433-44.
 113. Fridkin SK, WR Jarvis. Epidemiology of nosocomial fungal infections. *Clin Microbiol Rev*. 1996; 9 (4): 499-511.
 114. D M Dixon, M M McNeil, M L Cohen, B G Gellin, J R La Montagne. Fungal infections: a growing threat. *Public Health Rep*. 1996; 111 (3): 226-35.
 115. Kramer A, I Schwebke, G Kampf. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis*. 2006; 6 (1): 130.
 116. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on *Candida* species. *Clin Infect Dis*. 1995; 20 (6): 1526-30.
 117. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. *Clin Infect Dis*. 1996; 22 Suppl 2: 89-94.
 118. Richardson MD. Changing patterns and trends in systemic fungal infections. *J Antimicrob Chemother*. 2005; 56 (suppl_1): i5-i11.
 119. Ana Belkin, Zeala Gazit, Nathan Keller, Ronen Ben-Ami, Anat Wieder-Finesod, Ana Novikov. *Candida auris* infection leading to nosocomial transmission, Israel, 2017. *Emerg Infect Dis*. 2018; 24 (4): 801-4.
 120. Spivak ES, KE Hanson. *Candida auris*: an emerging fungal pathogen. *J Clin Microbiol*. 2018; 56 (2): e01588-17.
 121. K Y Chen, S C Ko, P R Hsueh, K T Luh, P C Yang. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. *Chest*. 2001; 120 (1): 177-84.
 122. Perlroth J, B Choi, B Spellberg. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. *Med Mycol J*. 2007; 45 (4): 321-46.
 123. Kordbacheh P, Zaini F, Kamali P, Ansari K, Safara M. Study on the Sources of Nosocomial Fungal Infections at Intensive Care Unit and Transplant Wards at a Teaching Hospital in Tehran. *Iran J Public Health*. 2005; 34 (2): 1-8.
 124. Bergogne-Berezin E. Current guidelines for the treatment and prevention of nosocomial infections. *Drugs*. 1999; 58 (1): 51-67.
 125. Dinkel RH, U Lebok. A survey of nosocomial infections and their influence on hospital mortality rates. *J Hosp Infect*. 1994; 28 (4): 297-304.
 126. YI W, Zhang Y, Zhang R. Economic Loss due to Hospital Infection: A Case Control Study. *Chinese Journal of Nosocomiology*. 2006; 10: 027.
 127. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *Am J Med*. 2002; 113 (1): 5-13.
 128. Bryan CS, KL Reynolds. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. *J Urol*. 1984; 132 (3): 494-7.
 129. T C Horan, D H Culver, R P Gaynes, W R Jarvis, J R Edwards, C R Reid. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. *Infect Control Hosp Epidemiol*. 1993; 14 (2): 73-80.
 130. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. *Infect Control Hosp Epidemiol*. 1996; 17 (8): 552-7.
 131. R W Haley, D H Culver, J W White, W M Morgan, T G Emori, V P Munn, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. *Am J Epidemiol*. 1985; 121 (2): 182-205.
 132. Jarvis WR. Benchmarking for prevention: the Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance (NNIS) system experience. *Infection*. 2003; 31 Suppl 2: 44-8.
 133. Sheykhsaran E, Hemmat N, Leylabadlo HE, Baghi HB. Bacterial and viral zoonotic infections: bugging the world. *Rev Med Microbiol*. 2022; 33 (1): 70-81.

Cite this article:

Sheykhsaran E, Ebrahimzadeh Leylabadlo H, Alinezhad F, Feizi H, Bannazadeh Baghi H. A New Insight into Nosocomial Infections: A Worldwide Crisis. *J Med Microbiol Infect Dis*, 2022; 10 (2): 64-74. DOI: 10.52547/JoMMID.10.2.64